[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660
|
[2] |
WANG M J, WANG Y T, FENG X S, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65: 15-21.
doi: S1201-9712(17)30227-8
pmid: 28935244
|
[3] |
中国临床肿瘤学会(CSCO). 原发性肝癌诊疗指南(2020)[M]. 人民卫生出版社, 2020.
|
|
Chinese society of clinical oncology (CSCO). Guidelines for diagnosis and treatment of primary liver cancer (2020)[M].People’s Health Publishing House[J], 2020. 2020.
|
[4] |
TAYOB N, LOK A S, DO K A, et al. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm[J]. Clin Gastroenterol Hepatol, 2016, 14(3): 469-475.e2.
doi: 10.1016/j.cgh.2015.07.049
|
[5] |
PAN B T, TENG K, WU C, et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes[J]. J Cell Biol, 1985, 101(3): 942-948.
pmid: 2993317
|
[6] |
YU W, HURLEY J, ROBERTS D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges[J]. Ann Oncol, 2021, 32(4): 466-477.
doi: 10.1016/j.annonc.2021.01.074
pmid: 33548389
|
[7] |
GE Y, MU W, BA Q, et al. Hepatocellular carcinoma-derived exosomes in organotropic metastasis, recurrence and early diagnosis application[J]. Cancer Lett, 2020, 477: 41-48.
doi: S0304-3835(20)30065-3
pmid: 32112905
|
[8] |
BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3): 1020-1022.
doi: 10.1002/hep.24199
pmid: 21374666
|
[9] |
KINOSHITA A, ONODA H, FUSHIYA N, et al. Staging systems for hepatocellular carcinoma: current status and future perspectives[J]. World J Hepatol, 2015, 7(3): 406-424.
doi: 10.4254/wjh.v7.i3.406
pmid: 25848467
|
[10] |
WILD C P, HALL A J. Primary prevention of hepatocellular carcinoma in developing countries[J]. Mutat Res Mutat Res, 2000, 462(2/3): 381-393.
|
[11] |
LI M Y, ZHAO C, CHEN L, et al. Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients[J]. Front Oncol, 2021, 11: 779567.
doi: 10.3389/fonc.2021.779567
|
[12] |
WHITESIDE T L. Cytokine assays[J]. BioTechniques, 2002, Suppl: 4-8, 10, 12-15.
|
[13] |
MONDELLO S, GUEDES V A, LAI C, et al. Circulating brain injury exosomal proteins following moderate-to-severe traumatic brain injury: temporal profile, outcome prediction and therapy implications[J]. Cells, 2020, 9(4): E977.
|
[14] |
VAUGHAN H A, HENNING M M, PURCELL D F, et al. The isolation of cDNA clones for CD48[J]. Immunogenetics, 1991, 33(2): 113-117.
pmid: 1999351
|
[15] |
TARAZONA R, DELGADO E, GUARNIZO M C, et al. Human prostasomes express CD48 and interfere with NK cell function[J]. Immunobiology, 2011, 216(1/2): 41-46.
doi: 10.1016/j.imbio.2010.03.002
|
[16] |
AALBERTS M, STOUT T A E, STOORVOGEL W. Prostasomes: extracellular vesicles from the prostate[J]. Reprod Camb Engl, 2014, 147(1): R1-R14.
|
[17] |
ZHU N Q, HOU J Y. Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma[J]. Cancer Cell Int, 2020, 20(1): 577.
doi: 10.1186/s12935-020-01672-3
pmid: 33292275
|